Gerdau S.A. Common Stock vs Merck & Co., Inc. — how do they compare? Gerdau S.A. Common Stock trades at $4.94 (market cap $9.16B), while Merck & Co., Inc. trades at $142.44 (market cap $351.28B). The key difference: Merck & Co., Inc. is far larger — about 38.3× Gerdau S.A. Common Stock's market cap, and Gerdau S.A. Common Stock pays the higher dividend (3.67%). Which is the better fit depends on your goals — on Pluang, investors hold Gerdau S.A. Common Stock for 0 Days and Merck & Co., Inc. for 98 Days on average.
| GGB | MRK | |
|---|---|---|
Market Cap | $9.16B | $351.28B |
Volume | 16,238,936 | 7,969,665 |
Sector | Basic Materials | Health |
52-Week High | $5.17 | $156.43 |
52-Week Low | $3.15 | $82.49 |
Typical Hold Time | 0 Days | 98 Days |
Enterprise Value | $11.10B | $398.04B |
Dividend Yield | 3.67% | 2.39% |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Merck (MRK) trades at $142.79, up 0.61% on the day, with a bearish technical signal despite beating earnings estimates in recent quarters. The company reported 2025 revenue of $65.01B and net income of $18.25B, with a high P/E ratio of 113.9 reflecting premium valuation. Recent news highlights Merck's acquisition of Terns Pharmaceuticals to bolster its oncology pipeline, while institutional investors have been increasing stakes.
The outlook is mixed: strong analyst consensus (68% buy ratings) and a $158.78 price target suggest upside, but high valuation and bearish technicals pose near-term risks. Key opportunities include pipeline expansion via M&A; risks involve integration challenges and patent pressures.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Gerdau is a steel producer with operations across the Americas. It makes long steel, specialty steel, and other products for construction and industrial markets.
Read more on GGB →Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →